| Autor: |
Ewing JC; Department of Haematological Oncology, Christie Hospital, Manchester M20 4BX, UK. jewing@picr.man.ac.uk, Robertson JD, Kell WJ, Burnett AK, Ryder D, Chang J, Morgenstern GR, Scarffe JH, Chopra R |
| Jazyk: |
angličtina |
| Zdroj: |
Hematology (Amsterdam, Netherlands) [Hematology] 2003 Apr; Vol. 8 (2), pp. 83-90. |
| DOI: |
10.1080/1024533031000090793 |
| Abstrakt: |
The role of autologous peripheral blood stem cell transplantation (APBSCT) in acute myeloid leukaemia (AML) remains controversial. The current study evaluated the application of APBSCT in a large consecutive series of patients with untreated AML, and compared outcome with a predictive model based on MRC AML10 data. Of 148 evaluable patients, 118 patients entered complete remission (CR) after induction therapy comprising three cycles of daunorubicin, cytosine arabinoside and oral 6-thioguanine. Of these patients, 68 (57%) proceeded to consolidation therapy with two courses of intermediate dose cytosine arabinoside, and stem cell mobilisation, and 40 of these patients (34%) underwent the APBSCT procedure after high dose busulphan conditioning. Harvest quality was the main factor precluding APBSCT. Five-year event-free survival (EFS) in patients who achieved CR was 38% and in APBSCT patients was 57%. There were no transplant-related deaths. No significant differences were demonstrated between observed and expected outcomes at 1 and 2 years, based on the predictive model derived from the MRC AML10 study. These data therefore indicate that only a third of eligible adult patients will undergo APBSCT. However, the results demonstrate favourable survival in such patients, with no transplant-related mortality. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
